Orgenesis Inc. (ORGS) Stock

Orgenesis Inc. is a leading biotech company specializing in the advancement of cell and gene therapies on a global scale. Founded in 2008 and headquartered in Germantown, Maryland, Orgenesis has distinguished itself through its innovative Point of Care (POCare) platform. This platform integrates a pipeline of licensed therapeutics designed for point-of-care treatment, utilizing closed automated systems. These systems are pivotal in ensuring compliant and efficient production of therapies near the patient, specifically tailored for autologous treatments.

Orgenesis focuses on developing customized processes for each therapy within its POCare network, emphasizing closed and automated processing systems. These systems are crucial for maintaining the integrity and efficacy of treatments, meeting stringent regulatory standards. The company's approach underscores its commitment to enhancing patient outcomes through accessible, state-of-the-art therapeutic solutions that are produced directly where patients receive care.

Formerly known as Business Outsourcing Service, Inc., Orgenesis rebranded in August 2011 to reflect its expanded focus on transformative biotechnological advancements. With a foundation built on cutting-edge POCare technology and a collaborative network, Orgenesis continues to pioneer new frontiers in cell and gene therapies, addressing critical medical needs and improving healthcare delivery worldwide.